REDWOOD
CITY, Calif., Jan. 21,
2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain,
announced that on January 7, 2025,
the Compensation Committee of the Company's Board of Directors
granted inducement restricted stock unit awards covering 21,026
shares of Nevro's common stock to 10 new non-executive employees to
induce them to accept employment with Nevro. Each award was granted
under the Nevro Corp. 2023 Inducement Award Plan and vests over a
three-year period, subject to continued employment with Nevro
through each vesting date.
Each award was granted as a material inducement to employment in
accordance with the NYSE Listed Company Manual Rule 303A.08.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 115,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes the Senza® SCS
system and support services for the treatment of chronic pain of
the trunk and limb and painful diabetic neuropathy.
Nevro also provides minimally invasive treatment options for
patients suffering from chronic sacroiliac joint ("SI joint") pain
and offers the most comprehensive portfolio of products in the SI
joint fusion space, designed to meet the preferences of physicians
and varying patient needs in order to improve outcomes and quality
of life for patients.
Senza®, Senza II®, Senza Omnia™, and HFX iQ are the
only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
Nevro's unique support services provide every patient with an HFX
Coach™ throughout their pain relief journey and every physician
with Nevrocloud™ insights for enhanced patient and practice
management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, Nevrocloud, RELIEF MULTIPLIED, HFX
AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks or
registered trademarks of Nevro Corp. Patents covering Senza HFX iQ
and other Nevro products are listed at Nevro.com/patents.
Bluetooth® and the Bluetooth symbol are registered
trademarks of their respective owners.
To learn more about Nevro, connect with us on LinkedIn, X,
Facebook, and Instagram.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302356628.html
SOURCE Nevro Corp.